1. Employing Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapy
   Dhruv Varshney et al, 2021, AAPS J CrossRef
2. An efficient and safe MUC1-dendritic cell-derived exosome conjugate vaccine elicits potent cellular and humoral immunity and tumor inhibition in vivo
   Haomiao Zhu et al, 2021, Acta Biomaterialia CrossRef
3. Comparison of mucin-1 in human breast cancer and canine mammary gland tumor: a review study
   Rana Vafaei et al, 2022, Cancer Cell Int CrossRef
4. Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine
   Shi-Hao Zhou et al, 2022, Front. Immunol. CrossRef
5. MUC Glycoproteins: Potential Biomarkers and Molecular Targets for Cancer Therapy
   Chameli Ratan et al, 2021, CCDT CrossRef
6. Adjuvant-Protein Conjugate Vaccine with Built-In TLR7 Agonist on S1 Induces Potent Immunity against SARS-CoV-2 and Variants of Concern
   Ru-Yan Zhang et al, 2022, ACS Infect. Dis. CrossRef
7. Glycolipid‐peptide conjugate vaccines elicit CD8 + T‐cell responses and prevent breast cancer metastasis
   Olivia K Burn et al, 2022, Clin & Trans Imm CrossRef
8. Advances in MUC1-Mediated Breast Cancer Immunotherapy
   Zhifeng Li et al, 2022, Biomolecules CrossRef
9. Breast Cancer Vaccine Containing a Novel Toll-like Receptor 7 Agonist and an Aluminum Adjuvant Exerts Antitumor Effects
   Shuquan Zhang et al, 2022, IJMS CrossRef
10. Advances in Tumor Antigen‐Based Anticancer Immunotherapy: Recent Progress, Prevailing Challenges, and Future Perspective
    Wei Shi et al, 2022, Advanced Therapeutics CrossRef
11. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer.
    Feng Ye et al, 2023, Mol Cancer CrossRef
12. Peptide Vaccines as Therapeutic and Prophylactic Agents for Female-Specific Cancers: The Current Landscape
    Manju Lekshmy et al, 2023, Pharmaceuticals CrossRef
13. Combination Therapy with a TLR7 Agonist and a BRD4 Inhibitor Suppresses Tumor Growth via Enhanced Immunomodulation
    Yong-Si Liu et al, 2024, IJMS CrossRef
14. MUC1 and MUC16: critical for immune modulation in cancer therapeutics
    Xinyi Chen et al, 2024, Front. Immunol. CrossRef
15. Toll‐like receptors in health and disease
    Kunyu Wang et al, 2024, MedComm CrossRef
16. Immunotherapy for HPV negative head and neck squamous cell carcinoma
    Binyumeng Jiang et al, 2024, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef